Pyxis Oncology Inc.

PYXS | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.34

+$0.15 (+4.70%)

Sep 22, 2026, 1:59 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+4.70%

(1D)

Rating

Updated: Aug 13, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $211.61M

1D Range

3.21 3.41

52W Range

1.03 5.55

Valuation (TTM)

PE -2.26

PB 17.67

EV/EBITDA -2.24

Valuation (NTM)

Forward PE N/A

Forward PEG 0.30

Price Target $7.67

Cash Flow

FCF Yield -33.6%

SBC Adj. FCF Yield -39.5%

SBC Impact -17.5%

Margins

Gross Margin 99.8%

Operating Margin -834.4%

FCF Margin -615.3%

Growth (CAGR)

Revenue 3Y | 5Y -25.5% | 41.5%

Dil EPS 3Y | 5Y -5.3% | 19.6%

FCF 3Y | 5Y -8.4% | 3.0%

Returns

ROA -161.6%

ROE -215.2%

ROIC -314.7%

Financial Health

Net Cash

$15.16M

Current Ratio 1.34

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipel...

Sector Healthcare

Industry Biotechnology

Employees 56

IPO Date Oct 7, 2021

Website www.pyxisoncology.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 2, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+139.52%

Buy (8)

Hold (0)

Sell (0)

Analyst Details ➞